BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24999703)

  • 1. Intense 18F-choline uptake after minor head injury: misleading PET/CT result in a patient with biochemical relapse of prostate adenocarcinoma.
    Leyendecker P; Imperiale A; Matern JF; Noël G; Namer IJ
    Clin Nucl Med; 2014 Nov; 39(11):1012-3. PubMed ID: 24999703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-fluorocholine uptake in a case of adrenal incidentaloma: possible diagnostic pitfall or potential tool for adrenocortical tumors characterization?
    Imperiale A; Cabral JF; Rust E; Flores-Turk G; Renard C; Hubele F; Detour J; Lang H; Gangi A; Namer IJ
    Clin Nucl Med; 2013 Feb; 38(2):e83-4. PubMed ID: 23334144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual lymph node metastases of prostate cancer detected by 18F-fluorocholine PET/CT.
    Pinaquy JB; Allard JB; Cornelis F; Pasticier G; De Clermont H
    Clin Nucl Med; 2015 Apr; 40(4):e255-7. PubMed ID: 25674860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
    Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
    Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidental detection of Hürthle cell adenoma by 18F-choline PET/CT scan in a patient with prostate cancer.
    Paone G; Treglia G; Bongiovanni M; Ruberto T; Ceriani L; Giovanella L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):340-1. PubMed ID: 23796426
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.
    Tabrizipour AI; Dunne M
    Clin Nucl Med; 2015 May; 40(5):e285-6. PubMed ID: 25608148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
    Gillebert Q; Huchet V; Rousseau C; Cochet A; Olivier P; Courbon F; Gontier E; Nataf V; Balogova S; Talbot JN;
    PLoS One; 2018; 13(2):e0191487. PubMed ID: 29425221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
    Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
    Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.
    Quero L; Vercellino L; de Kerviler E; Mongiat-Artus P; Culine S; Merlet P; Ravery V; Meria P; Desgrandchamps F; Hennequin C
    Clin Nucl Med; 2015 Nov; 40(11):e492-5. PubMed ID: 26252326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer.
    Schillaci O; Calabria F; Tavolozza M; Cicciò C; Carlani M; Caracciolo CR; Danieli R; Orlacchio A; Simonetti G
    Nucl Med Commun; 2010 Jan; 31(1):39-45. PubMed ID: 19972635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake.
    Balogova S; Huchet V; Egrot C; Michaud L; Paycha F; Kerrou K; Montravers F; Cussenot O; Talbot JN
    Clin Nucl Med; 2013 Mar; 38(3):200-2. PubMed ID: 23354033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.
    Bauman G; Belhocine T; Kovacs M; Ward A; Beheshti M; Rachinsky I
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):45-55. PubMed ID: 21844889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer.
    Lamanna G; Tabouret-Viaud C; Rager O; Jorcano S; Vees HJ; Seimbille Y; Zaidi H; Ratib O; Buchegger F; Miralbell R; Zilli T; Garibotto V
    Clin Nucl Med; 2017 May; 42(5):e242-e246. PubMed ID: 28240662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.